-- No Shareholder Action Required at This Time -- PARSIPPANY, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today confirmed that DOMA Perpetual Capital Management LLC (“DOMA”) has nominated three candidates to stand for election to the Pacira Board of Directors (the “Board”) at the Company’s 2025 Annual Meeting of Stockholders. Pacira issued the follo ...

NEW YORK, March 12, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsu ...

Yes, the market has certainly seen its share of volatility recently. It’s led to some treacherous slides in equity prices. It seems that the high beta names are really getting slapped down. In most cases, the mega caps have stood in relatively well. Tuesday’s move to the 200-day on the S&P 500 brought out the bargain shoppers too. Many stocks managed to push into positive territory.On a bounce from those lows, resist the urge to buy everything that moves. Rather, look for stocks with strong earnings trends ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline.So what: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to d ...

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=132953&from=4 CLASS PERIOD: Augu ...

Core Insights - Pacira BioSciences reported fourth-quarter 2024 adjusted earnings of 91 cents per share, exceeding the Zacks Consensus Estimate of 86 cents and up from 89 cents in the same quarter last year [1][2] - Total revenues for the fourth quarter reached $187.3 million, a 3% increase year over year, but slightly missed the Zacks Consensus Estimate by 0.03% [2][10] Revenue Breakdown - The company's revenue primarily comes from product sales, specifically from its three marketed drugs: Exparel, Zilretta, and iovera. No royalty revenues were recognized in the fourth quarter [3] - Exparel's net product sales were $147.7 million, a 3% increase from the previous year, surpassing the Zacks Consensus Estimate of $145.3 million [4] - Zilretta's net product sales reached $33.1 million, up 15% year over year, exceeding the Zacks Consensus Estimate of $30.7 million [6] - iovera's net product sales were $6.5 million, a 7% increase from the year-ago quarter, slightly beating the Zacks Consensus Estimate of $6.4 million [7] Expense Analysis - Research and development (R&D) expenses (excluding stock-based compensation) were $22 million, a 33% increase from the previous year due to higher product development and clinical study costs [8] - Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) totaled $70.6 million, a 23% increase year over year, driven by investments in commercial and market access organizations [9] Financial Performance - For the full year 2024, Pacira recorded total revenues of $701 million, a 4% increase from 2023, but slightly below the Zacks Consensus Estimate of $701.9 million [10] - Adjusted earnings for 2024 were $3.20 per share, matching the Zacks Consensus Estimate and up from $2.81 in 2023 [10] Future Guidance - For 2025, Pacira expects total revenues to be in the range of $725-$765 million, with an adjusted gross margin projected between 76% and 78% [11] - Adjusted R&D expenses are anticipated to be between $90 million and $105 million, while adjusted SG&A expenses are expected to range from $290 million to $320 million [11] Recent Developments - The FDA approved a new Smart Tip for the iovera system to manage chronic low back pain, and Pacira secured a patent protecting Exparel's chemical composition until 2044 [12] - New phase I data for PCRX-201 showed improvement in knee pain and function for at least two years, with a favorable safety profile [13]

Financial Data and Key Metrics Changes - The company reported record revenues of $701 million for 2024, at the high end of the guided range [7] - Non-GAAP gross margin for Q4 was 79%, driven by improved margins for EXPAREL and ZILRETTA [46] - Adjusted EBITDA for the quarter was $62.5 million, indicating strong operational performance [46] Business Line Data and Key Metrics Changes - EXPAREL sales increased to $147.7 million in Q4 2024 from $143.9 million in Q4 2023 [45] - ZILRETTA sales rose to $33.1 million in Q4 2024 compared to $28.7 million in Q4 2023 [45] - Iovera sales were $6.5 million in Q4 2024, up from $6.0 million in Q4 2023 [45] Market Data and Key Metrics Changes - The NOPAIN Act now provides a reimbursement pathway for 18 million outpatient surgical procedures, with 6 million under CMS coverage and 12 million under commercial coverage [13] - The company has seen commercial payers adopting NOPAIN-like policies, doubling the previous commercial coverage map to approximately 40 million covered lives [17][18] Company Strategy and Development Direction - The company is focused on executing its 5/30 strategy, aiming for double-digit CAGR in product revenues over the next five years and expanding its innovative pipeline [9][11] - The acquisition of GQ Bio aligns with the 5/30 strategy, adding a high-capacity local delivery platform for genetic medicines [30][31] - The company plans to establish at least five clinical or commercial partnerships by 2030 to enhance its market presence [41] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the early signs of progress with the NOPAIN initiative, although they acknowledged that customer adoption will take time [62][63] - The company anticipates a more meaningful uptick in utilization and reimbursement in the second half of 2025 [51][80] - Management emphasized a disciplined approach to capital allocation, balancing growth investments with shareholder returns [49][74] Other Important Information - The company exited Q4 2024 with $485 million in cash and investments, positioning it well for future growth [47] - The board has undergone significant refreshment, reducing the average tenure of directors to less than five years [43] Q&A Session Summary Question: Can you discuss the assumptions for NOPAIN and the potential impediments to rapid uptake? - Management indicated that it will take time for customers to gain traction with NOPAIN, with early signs of progress being encouraging [62][63] Question: Are you seeing successful reimbursement and penetration into new accounts? - Management noted that while it is early days, they are seeing good traction and some commercial payer wins [66][68] Question: What is the company's approach to capital allocation given the growth potential? - Management emphasized a disciplined approach to capital allocation, focusing on funding current operations and innovation while managing the balance sheet [74] Question: Can you provide insight into the relative contributions of the product portfolio for 2025? - Management expects EXPAREL to remain the flagship product, with plans to support ZILRETTA and iovera as well [78] Question: What are the implications of the competitive landscape for the 5/30 growth strategy? - Management expressed confidence that there will not be a risk of generic launches in the near future, supporting their growth projections [82]

Core Insights - Pacira (PCRX) reported revenue of $187.25 million for the quarter ended December 2024, reflecting a 3.3% increase year-over-year, with EPS at $0.91 compared to $0.89 in the same quarter last year [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $187.31 million, resulting in a surprise of -0.03%, while the EPS exceeded the consensus estimate of $0.86 by 5.81% [1] Revenue Breakdown - Net product sales for iovera were $6.45 million, surpassing the estimated $6.36 million, marking a 6.9% increase year-over-year [4] - Net product sales for EXPAREL reached $147.68 million, exceeding the average estimate of $145.33 million, representing a 2.6% year-over-year growth [4] - Total net product sales amounted to $187.25 million, compared to the average estimate of $183.38 million, indicating a 4.2% year-over-year increase [4] - Net product sales for ZILRETTA were $33.12 million, exceeding the estimated $30.72 million, with a year-over-year change of 15.4% [4] Stock Performance - Over the past month, Pacira's shares have returned -2.1%, slightly better than the Zacks S&P 500 composite's -2.2% change [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), suggesting potential outperformance against the broader market in the near term [3]

Company Performance - Pacira reported quarterly earnings of $0.91 per share, exceeding the Zacks Consensus Estimate of $0.86 per share, and showing a slight increase from $0.89 per share a year ago, representing an earnings surprise of 5.81% [1] - The company posted revenues of $187.25 million for the quarter ended December 2024, which was slightly below the Zacks Consensus Estimate by 0.03%, but an increase from $181.24 million year-over-year [2] - Over the last four quarters, Pacira has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - Pacira shares have increased approximately 35.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is $0.82 on revenues of $175.59 million, and for the current fiscal year, it is $3.59 on revenues of $735.96 million [7] - The estimate revisions trend for Pacira is currently favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Pacira belongs, is currently ranked in the top 28% of over 250 Zacks industries, suggesting a positive outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Sales Performance - Total net product sales increased by 4% to $697.2 million in 2024, compared to $672.2 million in 2023[484] - EXPAREL sales rose by 2% to $549.0 million in 2024, driven by a 4% increase in gross vial volume[484] - ZILRETTA revenue increased by 6% to $118.1 million, attributed to a 4% rise in net selling price per unit[485] - iovera° sales grew by 16% to $22.8 million, primarily due to a 20% increase in Smart Tip volume[485] Cost and Expenses - Cost of goods sold decreased by 8% to $170.4 million in 2024, resulting in a gross margin increase from 73% to 76%[488] - Total research and development expense increased by 7% in 2024 to $81,577,000 compared to $76,257,000 in 2023, representing 12% of total revenue[490] - Clinical and preclinical development expenses rose by 38% in 2024 to $33,696,000, driven by ongoing trials and start-up expenses for new projects[491] - Product development and manufacturing capacity expansion expenses decreased by 8% in 2024 to $30,803,000, primarily due to the completion of pre-commercial scale-up activities[492] - Selling, general and administrative expenses increased by 9% in 2024 to $294,099,000 compared to $269,441,000 in 2023, accounting for 42% of total revenue[497] - Sales and marketing expenses grew by 12% in 2024 to $172,015,000, fueled by investments in awareness and education programs[498] - General and administrative expenses increased by 5% in 2024 to $87,227,000, mainly due to consulting costs and compensatory expenses related to executive transitions[499] - Stock-based compensation decreased by 15% in 2024 to $7,381,000, attributed to fewer equity awards granted and headcount vacancies[495] Research and Development - Research and development expenses include costs for clinical trials and product development, contributing to the advancement of PCRX-201[489] - The company received U.S. Patent No. 12,156,940 for EXPAREL, expected to provide protection until July 2044[480] - A new Smart Tip for managing chronic low back pain was FDA-cleared in January 2025, enhancing treatment options[480] Acquisitions and Growth Strategy - The acquisition of GQ Bio for approximately $32 million aims to advance the company's growth strategy in innovative biopharmaceuticals[480] - The company plans to expand the use of its products and enhance manufacturing capacity to support growth initiatives[478] - The company completed the GQ Bio Acquisition in February 2025, with a net purchase price including approximately $8 million to be paid over three years[541] - Potential milestone payments related to the Flexion Acquisition could total up to $372.3 million if certain conditions are met[534] Financial Position - The company reported an accumulated deficit of $206.4 million and cash and cash equivalents of $484.6 million as of December 31, 2024[514] - In 2024, net cash provided by operating activities was $189.4 million, an increase of $34.7 million from $154.6 million in 2023, primarily due to increased revenue and lower interest paid[517] - Net cash used in investing activities in 2024 was $83.3 million, reflecting $72.6 million in available-for-sale investment purchases and $10.6 million in capital expenditures[518] - Net cash provided by financing activities in 2024 was $17.4 million, primarily from $287.5 million in proceeds from the issuance of 2029 Notes[521] - The company announced a share repurchase program in May 2024, authorizing up to $150.0 million of common stock repurchases, effective until December 31, 2026[524] Debt and Financing - As of December 31, 2024, the outstanding principal on the TLA Term Loan was $105.3 million, with borrowings at a rate of 7.43%[528] - The company has raised $344.5 million in net proceeds from the sale of common stock and other equity securities since inception[523] - Future capital requirements may necessitate additional debt or equity financing, with no committed external sources currently available[536] - The maximum remaining potential payments related to contingent consideration from the Flexion Acquisition is $372.3 million as of December 31, 2024[549] - A hypothetical 10 percent increase in forecasted annual growth rates would increase the value of contingent consideration liability associated with the Flexion Acquisition by $6.3 million[549] - The outstanding principal on the TLA Term Loan was $105.3 million as of December 31, 2024, with a fixed interest rate of 7.43%[558] - A hypothetical 100 basis point increase in interest rates would increase interest expense over the next 12 months by approximately $1.1 million based on TLA Term Loan balances[558] - The estimated fair value of the 2025 Notes was $971 per $1,000 principal amount as of December 31, 2024, with $202.5 million of principal remaining outstanding[556] - The estimated fair value of the 2029 Notes was $861 per $1,000 principal amount as of December 31, 2024, with all $287.5 million of principal remaining outstanding[557] Risks and Legal Matters - The company incurred costs related to legal and regulatory matters, including those for developing and defending intellectual property[543] - The company’s accounts receivable are primarily concentrated with three large wholesalers, which poses a risk of material adverse impact on financial condition if non-performance occurs[560] - The company’s investment activities aim to preserve principal while maximizing income, with a hypothetical 100 basis point increase in interest rates potentially reducing the fair value of available-for-sale securities by approximately $0.8 million[555] - Goodwill impairment recorded in 2024 was $163,243,000 due to the approval of a generic competitor and a court ruling affecting patent validity[503] - The goodwill balance of $163.2 million was fully impaired during the three months ended September 30, 2024, due to a decrease in common stock price and FDA approval of a generic competitor[553]